We use cookies to improve your experience on this site. By viewing our pages, you give us consent to use cookies. Find out more.

Don’t invest unless you’re prepared to lose all the money you invest. NextFin promotes high - risk investments and you are unlikely to be protected if something goes wrong.
Take 2 minutes to learn more.

Equity Crowdfunding Pitches

Showing results
Thymia aims to empower clinicians with cutting-edge Neuroscience and AI objectively identify and track mental illness using speech, facial movements and behaviour patterns, enabling personalised, efficient treatment and accurate remote monitoring. They have a large dataset, successful sales, and are raising funds for medical regulation, ADHD expansion, and patent filings. 
days to go: Expired investment: £1,126,464
Providing convenient and affordable healthcare to patients either at home or their workplace. Practitioners can visit patients and offer a range of medical treatments including vaccinations, testing, physiotherapy and primary care. Qured have been highly successful in London and are growing at an alarming rate, ready to help the whole of the UK.
days to go: Expired investment: £763,160
Handsome are one of the leading brands of back care stocked in over 1000 stores such as boots and CVS Pharmacy. They stock a comprehensive range of award winning products for pain relief and posture management and aim to become the leading consumer brand in back care through their brand BAC< BackPainHelp.
days to go: Expired investment: £514,530
A technological healthcare service allowing patients to discuss any concerns with a GP, clinician or specialists via video consultations, home visits, or appointments at the clinic. DocNoc launched less than 12 months ago and has over 160 NHS and private sector doctors and clinics registered on the service. The company's business model is easily flexible and aim to launch DocNoc internationally.
days to go: Expired investment: £269,710
Carocell Bio is an early-stage Research and Design (R&D) company aiming to develop nanoparticle-based, novel peptide anti-inflammatories to treat atopic dermatitis/eczema (AD) and other serious inflammatory diseases. It argues that millions of people continue to be affected by debilitating skin ailments, which in turn, escalates the development of new pharmaceutical drugs. The company asserts that the anti-inflammatory therapeutics market will reach US$122.6 billion by 2025 from US$95.9 billion in 2019. The company aims to be a major contender in this market. Carocell Bio has also been awarded an Innovate UK grant of £390,874. The company is seeking £1 million in equity investment over the next 12 months to show that their compounds work in human tissue biopsies of several inflammatory diseases.

Pitch Rated

45%

Insufficient Data

rating powered by

CROWD RATING™

days to go: Expired investment: Withheld
Rightangled are a CQC registered healthcare provider specialising in genetic testing and is backed by the NHS England. They have designed and filed a patent for their Cardiac genetic test and are now seeking to expand their testing and telemedicine service into new markets and new tests.
days to go: Expired investment: £433,290
Anastasis Biotec (AB) is a company that is developing a human protein-based product, Syntana-4 (S-4), that inhibits Cancer Stem Cells (CSC) - the growth engine of cancer. The global cancer drug market was at ~$200 billion in 2019. S-4 will initially target use for patients with relapsed prostate cancer which caused 3.8% of global cancer deaths in 2018. The company asserts that S-4 will have low manufacturing costs, making it affordable, enabling ‘mass-market’ sales. AB has raised £450,000 in equity convertible loans and grants in 2019 & 2020, including an Innovate-UK award. It is also aiming to progress S-4 further in collaboration with the University of Chicago’s cancer stem cell therapeutics Research and development (R&D) program. The company will use the investment to complete lab-testing before starting clinical trials.

Pitch Rated

53%

Insufficient Data

rating powered by

CROWD RATING™

days to go: Expired investment: £270,543
envoPAP is a company that specialises in manufacturing printing and packaging materials from agricultural waste. Started in 2015, the company has achieved £7.3 million in revenues across 45 countries. The European packaging market is valued at over £100 billion and the European Union (EU)are looking to ban some single-use plastic products with effect from 2021, envoPAP aims to capitalise on these developments. The year 2019 saw envoPAP introducing its product 'envoBarrier’- a material resistant to oil, water, and grease which won the 'Packaging Innovation of the Year' at the Business Green Technology Awards. In 2020, envoPAP became a certified B Corporation rendering it a business that balances purpose and profit. The investment will be used to protect its Intellectual Property (IP) and expand its team.

Pitch Rated

75%

Overall

rating powered by

CROWD RATING™

days to go: Expired investment: £381,128
Qure’s aim is to provide individual healthcare that is both affordable and highly convenient, becoming the platform of choice for both patients and practitioners. Qure offer 24/7 private healthcare, without the huge price tag that is usually associated with these kinds of services. 
days to go: Expired investment: £1,162,206
Gripit offers uniquely designed plasterboard fixings, which can hold tremendous loads upto 113kgs. These light weighted and easy to install products are exported to over 32 countries, thereby raising over £4m in the last Crowdcube campaigns. In 2008, Mr. Jordan Daykin invented gripit drywall anchor when he was just 13 years old. In 2014, he became the youngest person to secure investment through BBC’s Dragon Den.  
days to go: Expired investment: £1,007,470
  • Internet Business Awards Category Award Winner 2015
  • Hertfordshire Business Awards Finalist 2014

As seen in:

  • The Guardian
  • Financial Times
  • Yahoo! Finance
  • The Times
  • The Daily Telegraph